{"id":"mebendazole-multivitamin","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mebendazole is a benzimidazole anthelmintic that binds to β-tubulin and inhibits microtubule polymerization in nematodes and other helminths, leading to immobilization and eventual death of the parasites. The addition of multivitamin supplementation addresses micronutrient deficiencies (iron, vitamin A, B vitamins, etc.) that commonly occur in populations with parasitic infections, improving overall health outcomes and potentially enhancing immune response.","oneSentence":"Mebendazole disrupts microtubule formation in parasitic worms, causing paralysis and death, while the multivitamin component addresses nutritional deficiencies often associated with helminthic infections.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:28.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Soil-transmitted helminth infections (roundworm, hookworm, whipworm) in children in endemic regions"},{"name":"Nutritional support in populations with high parasitic infection burden"}]},"trialDetails":[{"nctId":"NCT00148629","phase":"PHASE3","title":"Treatment and Prevention of Severe Anemia in Pregnant Zanzibari Women","status":"COMPLETED","sponsor":"Cornell University","startDate":"2004-04","conditions":"Anemia, Low Birth Weight, Neonatal Mortality","enrollment":2500},{"nctId":"NCT00116493","phase":"PHASE3","title":"Severe Anemia Treatment Trials, Pakistan","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2004-04","conditions":"Anemia","enrollment":1009}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Mebendazole + Multivitamin","genericName":"Mebendazole + Multivitamin","companyName":"Johns Hopkins Bloomberg School of Public Health","companyId":"johns-hopkins-bloomberg-school-of-public-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mebendazole disrupts microtubule formation in parasitic worms, causing paralysis and death, while the multivitamin component addresses nutritional deficiencies often associated with helminthic infections. Used for Soil-transmitted helminth infections (roundworm, hookworm, whipworm) in children in endemic regions, Nutritional support in populations with high parasitic infection burden.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}